Abstract
Opportunistic fungal infections are significant causes of mortality and morbidity especially among the immunocompromised hosts. There is now increasing array of drugs available for their treatment. Amphotericin B is the most established and widely used antifungal agent and lipid-complexed amphotericin B preparations are introduced recently. The imidazole and triazole drugs have specific roles to play on the management of these patients. However, antifungal therapy is still limited by the lack of effective agents, lack of early diagnostic techniques to identify infection in its early stages and the developement of resistance. There are also few comparative studies of drugs within the increasing number of antifungal agents which would Provide a reliable basis for choice.
Keywords
Opportunistic fungal infections Treatment
KJMM
1997 June;2(1):9-16(8). Epub 2016 February 25
Copyright © 1997 by Korean Journal of Medical Mycology
Language
Korean/English
Author
Jin Hong Yoo; Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
Wan Shik Shin; Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
Corresponding
Wan Shik Shin, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Publication history
Acknowledgements
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Jin Hong Yoo
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
Wan Shik Shin
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
